The stock of Uniqure NV (NASDAQ:QURE) reached all time low today, Nov, 24 and still has $6.49 target or 3.00% below today’s $6.69 share price. This indicates more downside for the $155.28 million company. This technical setup was reported by Barchart.com. If the $6.49 PT is reached, the company will be worth $4.66M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock increased 0.30% or $0.02 on November 23, hitting $6.69. About 208,957 shares traded hands. Uniqure NV (NASDAQ:QURE) has declined 53.77% since April 22, 2016 and is downtrending. It has underperformed by 59.18% the S&P500.
Analysts await Uniqure NV (NASDAQ:QURE) to report earnings on December, 5. They expect $-0.86 earnings per share, down 14.67% or $0.11 from last year’s $-0.75 per share. After $-0.98 actual earnings per share reported by Uniqure NV for the previous quarter, Wall Street now forecasts -12.24% EPS growth.
Uniqure NV (NASDAQ:QURE) Ratings Coverage
Out of 11 analysts covering uniQure N.V. (NASDAQ:QURE), 8 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 73% are positive. uniQure N.V. has been the topic of 21 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock has “Overweight” rating given by Piper Jaffray on Friday, August 28. On Friday, August 28 the stock rating was maintained by WallachBeth Capital with “Buy”. The stock of Uniqure NV (NASDAQ:QURE) has “Outperform” rating given on Tuesday, September 22 by Leerink Swann. The firm has “Buy” rating given on Monday, November 30 by TH Capital. The stock has “Hold” rating given by Jefferies on Tuesday, November 22. The stock of Uniqure NV (NASDAQ:QURE) has “Buy” rating given on Thursday, August 4 by H.C. Wainwright. The rating was reinitiated by Roth Capital on Monday, November 30 with “Buy”. The firm earned “Outperform” rating on Monday, September 21 by Oppenheimer. The company was reinitiated on Wednesday, February 24 by H.C. Wainwright. The stock of Uniqure NV (NASDAQ:QURE) earned “Buy” rating by WallachBeth Capital on Wednesday, June 15.
According to Zacks Investment Research, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.”
Another recent and important Uniqure NV (NASDAQ:QURE) news was published by Fool.com which published an article titled: “Why uniQure NV Stock Skyrocketed Today” on April 06, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.